Expanded autologous progeny of an adult CD34+ stem cell subset in recent tibial fractures
Tibial Fractures
Enrolment: 0 · Results not recorded
Loading the evidence…
Biologic · ChEMBL NOT QUERIED: autologous cell therapy, no chemical entity; resolved=false by entity class. 48 raw hits, 6 recorded. CLASS-LEVEL FLAG: the recorded trials are autologous CD34+ progenitor cell therapy in ischaemia, stroke, myocardial infarction and fracture, i.e. the same CD34+ selected cell platform but NOT the specific differentiated blood-derived product (dBDPC). NCT00632034 (CD34+ progeny in recent tibial fractures) is the only injury-repair indication and is WITHDRAWN at zero enrolment. NCT01351610 EXCLUDED: explicitly CD34-NEGATIVE MSC.
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Tibial Fractures
Enrolment: 0 · Results not recorded
Critical Limb Ischemia
Enrolment: 45 · Results not recorded
Ischemia · Ulcer · Gangrene · Peripheral Vascular Diseases
Enrolment: 15 · Results not recorded
Stroke, Acute
Enrolment: 5 · Results not recorded
Chronic Myocardial Ischemia
Enrolment: 1 · Results not recorded
Myocardial Infarction
Enrolment: 31 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute liver injury induced by CCl4 1.2 ml/kg diluted 1:1 in olive oil intraperitoneally
Intravenous dBDPCs given one day after CCl4 increased survival, restored body weight, lowered liver enzymes and necrosis, and promoted liver regeneration compared with saline.
Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.